ClinicalTrials.gg

Program

vadadustat

Also written as “Vadadustat”, “AKB-6548” and “MT-6548”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic, led by 2 companies.

Furthest: phase 3, since Jan 4, 201636 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akebia Therapeutics320 open or runningphase 3since Jan 4, 2016Nov 5, 2010none ahead
Tanabe Pharma40 open or runningphase 3since Oct 30, 2017Oct 30, 2017none ahead

Also a collaborator on its studies: Otsuka.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Nov 5, 2010.

  1. Dec 27, 2017Phase 3 study in AnemiaTanabe Pharma · NCT03402386 · 42 enrolled · Japan
  2. Feb 14, 2018Phase 3 study in AnemiaTanabe Pharma · NCT03439137 · 323 enrolled · Japan
  3. Mar 5, 2018Phase 3 study in AnemiaTanabe Pharma · NCT03461146 · 24 enrolled · Japan
  4. Jun 12, 2018Phase 1 study in HealthyAkebia Therapeutics · NCT03639155 · 50 enrolled · United States
  5. Aug 31, 2018Phase 1 study in HealthyAkebia Therapeutics · NCT03657290 · 54 enrolled · United States
  6. Dec 3, 2018Phase 2 study in AnemiaAkebia Therapeutics · NCT03799627 · 175 enrolled · United States
  7. Dec 27, 20185 phase 1 studiesAkebia Therapeutics · NCT03801759, NCT03801746, NCT03801733 and 2 more
  8. Jun 18, 2019Phase 1 study in AnemiaAkebia Therapeutics · NCT03992066 · 46 enrolled · United States
  9. Mar 5, 2020Phase 1 study in Healthy VolunteersAkebia Therapeutics · NCT04299633 · 54 enrolled · Canada
  10. Mar 16, 2020Phase 3 study in AnemiaAkebia Therapeutics · NCT04313153 · 319 enrolled · United States, Czechia, Hungary and more
  11. Nov 2, 2020Phase 2 study in Renal Insufficiency, ChronicAkebia Therapeutics · NCT04707573 · 22 enrolled · United States
  12. Jan 12, 2021Phase 3 study in AnemiaAkebia Therapeutics · NCT04707768 · 456 enrolled · United States
  13. Sep 28, 20212 phase 3 studies in AnemiaAkebia Therapeutics · NCT05082584, NCT05082571
  14. Mar 27, 2025Phase 3 study in Renal Insufficiency, ChronicAkebia Therapeutics · NCT06901505 · 353 enrolled · United States

TargetBeta

“Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
roxadustatruleAstellas Pharmaphase 447
daprodustatruleGlaxoSmithKlinephase 333

Studies

All 36 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06901505Renal Insufficiency, Chronic · United States3CompletedAkebia TherapeuticsAug 12, 2026353
NCT05082584Anemia · United States3WithdrawnAkebia TherapeuticsJul 20260
NCT05082571Anemia · United States3WithdrawnAkebia TherapeuticsJul 20260
NCT04707768Anemia · United States3CompletedAkebia TherapeuticsJan 6, 2023456
NCT04707573Renal Insufficiency, Chronic · United States2CompletedAkebia TherapeuticsSep 24, 201022
NCT04313153Anemia · United States, Czechia, Hungary and more3CompletedAkebia TherapeuticsNov 26, 2021319
NCT04299633Healthy Volunteers · Canada1CompletedAkebia TherapeuticsAug 2, 202054
NCT03992066Anemia · United States1CompletedAkebia TherapeuticsMay 5, 202046
NCT03801759Drug Interaction Potentiation · Canada1CompletedAkebia TherapeuticsSep 30, 201862
NCT03801746Drug Interaction Potentiation · Canada1CompletedAkebia TherapeuticsAug 15, 201840
NCT03801733Drug Interaction Potentiation · Canada1CompletedAkebia TherapeuticsNov 24, 2018134
NCT03799848Hepatic Impairment · United States1CompletedAkebia TherapeuticsOct 18, 201824
NCT03789032Drug Interaction Potentiation · Canada1CompletedAkebia TherapeuticsNov 9, 201820
NCT03799627Anemia · United States2CompletedAkebia TherapeuticsJun 5, 2020175
NCT03657290Healthy · United States1CompletedAkebia TherapeuticsOct 16, 201854
NCT03639155Healthy · United States1CompletedAkebia TherapeuticsMay 23, 201850
NCT03461146Anemia · Japan3CompletedTanabe PharmaDec 3, 201824
NCT03439137Anemia · Japan3CompletedTanabe PharmaDec 12, 2018323
NCT03402386Anemia · Japan3CompletedTanabe PharmaNov 22, 201842
NCT03329196Anemia · Japan3CompletedTanabe PharmaJan 8, 2019304
NCT03242967Anemia · United States3WithdrawnAkebia TherapeuticsFeb 12, 20180
NCT03140722Anemia · United States2TerminatedAkebia TherapeuticsMar 21, 20182
NCT03054350Anemia · Japan2CompletedAkebia TherapeuticsOct 24, 201760
NCT03054337Anemia · Japan2CompletedAkebia TherapeuticsJul 4, 201751
NCT02892149Anemia · United States, Argentina, Australia and more3CompletedAkebia TherapeuticsJan 16, 20203,554
NCT02865850Anemia · United States, Argentina, Brazil and more3CompletedAkebia TherapeuticsJan 31, 2020369
NCT02680574Anemia · United States, Argentina, Australia and more3CompletedAkebia TherapeuticsJun 18, 20201,725
NCT02648347Anemia · United States, Argentina, Australia and more3CompletedAkebia TherapeuticsJun 4, 20201,751
NCT02502500Healthy Volunteers1CompletedAkebia TherapeuticsJul 201512
NCT02412449Anemia · United States1CompletedAkebia TherapeuticsApr 201518
NCT02327546Anemia · United States1CompletedAkebia TherapeuticsDec 201410
NCT02260193Anemia · United States2CompletedAkebia TherapeuticsJul 22, 201594
NCT02062203Anemia · United States1CompletedAkebia TherapeuticsApr 201450
NCT01906489Anemia · United States2CompletedAkebia TherapeuticsSep 3, 2014210
NCT01381094Anemia · United States2CompletedAkebia TherapeuticsFeb 16, 201293
NCT01235936Anemia · United States2CompletedAkebia TherapeuticsApr 13, 201110

How it is read

Names in the registry

  • “Vadadustat”, 19 entries
  • “AKB-6548”, 8 entries
  • “MT-6548”, 4 entries
  • “vadadustat”, 4 entries
  • “vadadustat reference tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.